- Home
- BMI vs RCUS Comparison
BMI vs RCUS Comparison
Compare BMI & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BMI | RCUS |
|---|---|---|
| Founded | 1905 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 3.8B |
| IPO Year | 1994 | 2018 |
Fundamental Metrics
Financial Performance| Metric | BMI | RCUS |
|---|---|---|
| Price | $133.29 | $29.54 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 10 |
| Target Price | ★ $170.13 | $31.90 |
| AVG Volume (30 Days) | 257.5K | ★ 1.1M |
| Earning Date | 04-17-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.36% | N/A |
| EPS Growth | ★ 13.24 | N/A |
| EPS | ★ 1.95 | N/A |
| Revenue | N/A | ★ $247,000,000.00 |
| Revenue This Year | $5.97 | N/A |
| Revenue Next Year | $7.17 | $45.62 |
| P/E Ratio | $69.43 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $112.09 | $11.30 |
| 52 Week High | $204.00 | $31.74 |
Technical Indicators
Market Signals| Indicator | BMI | RCUS |
|---|---|---|
| Relative Strength Index (RSI) | 51.47 | 52.69 |
| Support Level | $126.18 | $25.94 |
| Resistance Level | $140.03 | $31.47 |
| Average True Range (ATR) | 3.50 | 1.23 |
| MACD | 0.29 | -0.10 |
| Stochastic Oscillator | 74.23 | 46.01 |
Price Performance
Historical ComparisonAbout BMI Badger Meter Inc.
Badger Meter is a provider of water management solutions. The company's solutions encompass measurement and control hardware, connectivity and communication, data visualization and software. Badger Meter has global operations, with the vast majority of revenue derived from the US.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.